Mitsue Kurasawa - Concepedia

Author

Mitsue Kurasawa

Chugai Pharma (United States)

Also Known As

Kurasawa Mitsue, MITSUE KURASAWA, Mitsue Kurasawa

Publications

953

Citations

H-Index

Concepts

All Affiliations

Chugai Pharma (United States)Roche (Japan)

About

Mitsue Kurasawa is an author at Chugai Pharma (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	453
2	Social Sciences	4	4	137
3	Cell Biology	3	3	121
4	Anesthesia	2	2	44
5	Health Sciences	1	1	81

Mitsue Kurasawa

Publications

857

Citations

H-Index

Page 1

	Year	Citations
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models Yoriko Yamashita‐Kashima, Shigeyuki Iijima, Keigo Yorozu, Clinical Cancer Research	2011	176
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model Chinami Masuda, Mieko Yanagisawa, Keigo Yorozu, International Journal of Oncology PathologyPharmacotherapyCancer BiologyTumor BiologyErlotinib Resistance	2017	82
Cerebral ischemia model with conscious mice Himori Norio, Hiroshi Watanabe, Akaike Nobuhide, Journal of Pharmacological Methods Conscious MiceCerebral Vascular RegulationIschemic StrokeNeurophysiologyBrain Injury	1990	81
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies Toshiki Iwai, Masamichi Sugimoto, Daiko Wakita, Oncotarget	2018	74
Bevacizumab improves the delivery and efficacy of paclitaxel Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Anti-Cancer Drugs Vascular PermeabilityTumor BiologyBreast OncologyOncologyMedicine	2010	67
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism Kazuo Nakamura, Mitsue Kurasawa European Journal of Pharmacology Different Mouse ModelsPsychoactive DrugUnderlying MechanismPsychiatryBehavioral Neuroscience	2001	65
Impact of bevacizumab in combination with erlotinib on <scp><i>EGFR</i></scp>‐mutated non–small cell lung cancer xenograft models with <scp>T790M</scp> mutation or <scp><i>MET</i></scp> amplification Koh Furugaki, Junko Fukumura, Toshiki Iwai, International Journal of Cancer	2015	38
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model Chinami Masuda, Masamichi Sugimoto, Daiko Wakita, Clinical & Experimental Metastasis	2019	35
Biomarkers for antitumor activity of bevacizumab in gastric cancer models Yoriko Yamashita‐Kashima, Kaori Fujimoto-Ouchi, Keigo Yorozu, BMC Cancer	2012	31
Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam Kazuo Nakamura, Mitsue Kurasawa, Yushiro Tanaka European Journal of Pharmacology NeuropsychologyMedicinePhysiologyBehavioral PharmacologyApomorphine-induced Hypoattention	1998	28

Page 1